CDK46 inhibitors in hormone receptorpositive HER2negative metastatic breast cancer

CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer

Dr Hikmat Abdel-Razeq speaks to ecancer at the WIN 2019 Symposium in Paris about the use of CDK4/6 inhibitors in hormone receptor-positive, HER2-negative, metastatic breast cancer. Dr Abdel-Razaq explains the issue of resistance when treated with...

More From BioPortfolio on "CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer"